ReviewBiomarkers in cancer2016
Biomarkers and Targeted Therapy in Pancreatic Cancer.
Review in Biomarkers in cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- ERK2-mediated phosphorylation of ZEB1 at S322 enhances PD-L1 expression and EMT, leading to pancreatic cancer progression.Cell communication and signaling : CCS · 2025Article
- Review
- CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.Cancer immunology, immunotherapy : CII · 2024Article
- The MyD88 inhibitor, ST2825, induces cell cycle arrest and apoptosis by suppressing the activation of the NF‑κB/AKT1/p21 pathway in pancreatic cancer.Oncology reports · 2023Article
- Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer.World journal of gastroenterology · 2023Review
- Identification of matrix-remodeling associated 5 as a possible molecular oncotarget of pancreatic cancer.Cell death & disease · 2023Article
- Unexpected long-term survival of Stage IV pancreatic cancer patient with synchronic liver metastases after multimodal therapy including upfront surgery.Journal of surgical case reports · 2023Article
- Molecular basis of epigenetic regulation in cancer diagnosis and treatment.Frontiers in genetics · 2022Review
- Four drug metabolism-related subgroups of pancreatic adenocarcinoma in prognosis, immune infiltration, and gene mutation.Open medicine (Warsaw, Poland) · 2022Article
- The clinical significance of microRNA-409 in pancreatic carcinoma and associated tumor cellular functions.Bioengineered · 2021Article
- Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy.Life (Basel, Switzerland) · 2021Review
- Transcription factors specificity protein and nuclear receptor 4A1 in pancreatic cancer.World journal of gastroenterology · 2021Review
- The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant).Cancer cell international · 2021Review
- Review
- Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts.OncoTargets and therapy · 2020Article
- Article
- Terphenyllin Suppresses Orthotopic Pancreatic Tumor Growth and Prevents Metastasis in Mice.Frontiers in pharmacology · 2020Article
- Research progress on long non-coding RNAs and their roles as potential biomarkers for diagnosis and prognosis in pancreatic cancer.Cancer cell international · 2020Review
- Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.Molecules (Basel, Switzerland) · 2019Review
- Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer.Metabolomics : Official journal of the Metabolomic Society · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%-3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Considering that pancreatic cancer shows early invasion and metastasis, critical research is needed to explore different aspects of the disease, such as elaboration of biomarkers, specific signaling pathways, and gene aberration. In this review, we highlight the biomarkers, the fundamental signaling pathways, and their importance in targeted drug delivery for pancreatic cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.